• Strong growth compared to H1 2022 in the Theranostics business in H1 2023 at +18.0% driven by a very good export performance (outside the United States)
• Slight acceleration in overall growth during Q2 2023 compared to Q2 2022 marked by solid commercial momentum in both Theradiag businesses
• Cash level as of June 30, 2023 higher than the plan: €5.7 million
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]